• Vaccine Name: SabRV-SIV
• Target Pathogen: Simian Immunodeficiency Virus
• Target Disease: Simian AIDS
• Vaccine Ontology ID: VO_0004704
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• env gene engineering:
  • Type: Recombinant vector construction
  • Description: To construct pSabRV1, first the EcoRI and XhoI sites upstream of the T7 promoter of pS1 were eliminated to create plasmid pS1XT. Then the 747-bp BstEII fragment of pMoV2.11—containing the duplicated 2Apro cleavage site, the 5-glycine spacer, and the EcoRI, NotI, and XhoI cloning sites—was swapped into pS1XT to create pSabRV1 (Crotty et al., 2001).
  • Detailed Gene Information: Click Here.
• env receptor binding subunit gene engineering:
  • Type: Recombinant vector construction
  • Description: To construct pSabRV1, first the EcoRI and XhoI sites upstream of the T7 promoter of pS1 were eliminated to create plasmid pS1XT. Then the 747-bp BstEII fragment of pMoV2.11—containing the duplicated 2Apro cleavage site, the 5-glycine spacer, and the EcoRI, NotI, and XhoI cloning sites—was swapped into pS1XT to create pSabRV1 (Crotty et al., 2001).
  • Detailed Gene Information: Click Here.
• gag-pol gene engineering:
  • Type: Recombinant vector construction
  • Description: To construct pSabRV1, first the EcoRI and XhoI sites upstream of the T7 promoter of pS1 were eliminated to create plasmid pS1XT. Then the 747-bp BstEII fragment of pMoV2.11—containing the duplicated 2Apro cleavage site, the 5-glycine spacer, and the EcoRI, NotI, and XhoI cloning sites—was swapped into pS1XT to create pSabRV1 (Crotty et al., 2001).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001052
  • Description: (Crotty et al., 2001)
• Preparation: New poliovirus vectors based on Sabin 1 and 2 vaccine strain viruses were constructed, and these vectors were used to generate a series of new viruses containing SIV gag, pol, env, nef, and tat in overlapping fragments (Crotty et al., 2001).
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccination Protocol: Seven animals were inoculated intranasally with 1 ml (5 × 10^7 PFU) of SabRV1-SIV on days 1, 3, 14, and 16, for a total of four immunizations. Nineteen weeks after the first series of inoculations, these same seven animals were given boosters of two intranasal inoculations of 1 ml (10^6 PFU/ml) of SabRV2-SIV, one at week 19 and a second at week 21 (Crotty et al., 2001).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The animals were challenged with 10^5 TCID50 of SIVmac251 intravaginally, using the SIVmac251 (5/98) stock (Crotty et al., 2001).
• Efficacy: Four of the seven vaccinated animals exhibited substantial protection against the vaginal SIV challenge (Crotty et al., 2001).